Cara Therapeutics (CARA) Misses Q3 EPS by 4c

Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.38), $0.04 worse than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target